Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

Award Number: R01HL173488
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome - PROJECT SUMMARY Mortality remains high (20%) for the 8,000 US children each year that develop pediatric acute respiratory distress syndrome (ARDS). No pharmacologic therapies have been identified that decrease the mortality risk from ARDS. This is likely due to underlying biologic heterogeneity among patients with ARDS that may result in some benefiting from a therapy whereas others are harmed, limiting the ability to find effective therapies in clinical trials of general cohorts. Inflammatory phenotypes have been described in ARDS that may help identify underlying biologic differences contributing to heterogeneity in treatment effect. However, these phenotypes cannot currently be identified in real-time. There is an urgent need for easily available markers to identify clinically relevant heterogeneity in patients with ARDS. Markers of dead space may be promising for this purpose. Dead space is area of the lung that receive ventilation without perfusion and reflects abnormal pulmonary perfusion (microvascular dysfunction, low cardiac output) and alveolar overdistension. With routine patient monitoring data (time-based capnography, blood gases), dead space can be estimated with the end tidal alveolar dead space fraction (AVDSf). We have found in single-center studies that AVDSf is more strongly associated with mortality risk than are markers of the severity of hypoxemia (oxygenation index [OI]) in early pediatric ARDS. Dead space may also be an attractive marker for identifying heterogeneity of treatment effect for therapies such as inhaled Nitric Oxide (iNO) that target pulmonary perfusion. iNO is a selective pulmonary vasodilator, with additional anti-inflammatory and anticoagulation effects, that is commonly used off-label for refractory hypoxemia in ARDS. But almost all clinical trials of iNO therapy have failed to demonstrate a benefit when enrolling general cohorts of patients or selecting patients based on severity of hypoxemia. One small pediatric trial found higher extracorporeal membrane oxygenation free survival suggesting the potential for some subgroups to benefit from iNO therapy. Our preliminary data suggest that iNO therapy decreases the AVDSf associated mortality risk and that a decline in AVDSf with iNO therapy is associated with improving plasma markers of microvascular dysfunction. Our central hypotheses are that the routinely available AVDSf is more strongly tied to mortality risk than OI and that AVDSf is an important marker of heterogeneity in the iNO treatment effect in patients with ARDS. These hypotheses will be tested through the following Specific Aims: 1) validate AVDSf for risk stratification of mortality in pediatric ARDS 2) determine if there is heterogeneity in treatment effect for iNO defined by AVDSf, and 3) detect the association between AVDSf and microvascular dysfunction trajectory and whether iNO therapy modifies the association. Demonstrating that AVDSf outperforms OI for mortality risk stratification in patients with ARDS and that AVDSf may identify the patients most likely to benefit from iNO therapy, has the potential to be frameshifting for future clinical trials of ARDS interventions, including those of iNO therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $784,784 )
2025	2025	CHILDREN'S HOSPITAL LOS ANGELES	4650 W SUNSET BLVD	LOS ANGELES	CA	90027	LOS ANGELES	USA	Lung Diseases Research	000	2	9/8/2025	NON-COMPETING CONTINUATION	$784,784
														Subtotal = $784,784

Issue Date FY: 2024 ( Subtotal = $873,736 )
2024	2024	CHILDREN'S HOSPITAL LOS ANGELES	4650 W SUNSET BLVD	LOS ANGELES	CA	90027	LOS ANGELES	USA	Lung Diseases Research	000	1	9/20/2024	NEW	$873,736
														Subtotal = $873,736

Grand Total All Awards = $1,658,520

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

Award Number: R01HL173488

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer